Fulvestrant, an estrogen receptor (ER) antagonist, is indicated for the treatment of:
- Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy;
- HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy;
- HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib as initial endocrine therapy or following disease progression on endocrine therapy;
- HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemacicilib in women with disease progression after endocrine therapy.
“Fresenius Kabi is pleased to continue the expansion of our oncology portfolio by offering Fulvestrant Injection,” said John Ducker, president and CEO of Fresenius Kabi USA. “We are pleased to be the only company offering this product in a room temperature stable formulation to assist clinicians in managing their costs and workflow.”
The product is supplied as two 5mL single-dose prefilled glass syringes, each containing 250mg per 5mL of Fulvestrant injection solution for intramuscular use. The prefilled syringes with attached plunger rods are presented in a tray with 2 pre-packaged safety needles for connection to the syringes.
For more information visit fresenius-kabi.com/us.